OMED

OncoMed Pharmaceuticals, Inc.
OMED

Overview Fund Activity
Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

42 hedge funds and large institutions have $13.1M invested in OncoMed Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
42
Holders Change
-12
Holders Change %
-22.22%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
15
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
HP
Harbourvest Partners
Massachusetts
$1.42M
2
Renaissance Technologies
Renaissance Technologies
New York
$911K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
$120K
4
BC
Birchview Capital
Vermont
$129K
5
Deutsche Bank
Deutsche Bank
Germany
$40K

Top Sellers

1
NC
Nexthera Capital
New York
$0
2
SI
Sofinnova Investments
California
$0
3
PA
Perceptive Advisors
New York
$1.28M
4
Vanguard Group
Vanguard Group
Pennsylvania
$266K
5
ECM
Endurant Capital Management
California
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
TRCT
51
Tower Research Capital (TRC)
New York
– -$36K -17,025 Closed
MAM
52
Meeder Asset Management
Ohio
– -$7K -3,084 Closed
1 2
3